ChemoCentryx, Inc. (NASDAQ:CCXI)

Stock Price: $51.99
+0 (0%)
Updated Oct 19, 2022 04:00 AM GMT+0000
Overview
Financials
Statistics
Profile
Chart
Market Cap 3.71B
Revenue 0
Gross Profit 0
Shares Out 71.36M
EPS (ttm)
PE Ratio 0.0000
Forward PE 0.0000
Dividend Rate (ttm) 0.0000
Dividend Yield 0.0000
Trading Day Oct 19
Last Price $51.99
Previous Close $51.99
Change ($) 0
Change (%) 0%
Day's Open 51.99
Day's Range 51.98 - 52
Day's Volume 0
52 Week Range 0 - 52

About ChemoCentryx, Inc.

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies.

ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration.

Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

News

Quick info

Country
United States
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Employees
133
CEO
Thomas Schall
Address
850 Maude Ave
Mountain View
California
94043-4022
Phone
16502102900
Ticker Symbol
CCXI
Reporting Currency
USD